ArfGAP with FG repeats 1Genealiases: HRB · RAB · RIP
Q-omics provides the consensus-scored AGFG1 profile across patient tissues and cancer cell-line models. AGFG1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, AGFG1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, AGFG1 RNA expression shows 19,954 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where AGFG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGFG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGFG1 survival associations across molecular data types. AGFG1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGFG1 RNA expression–survival associations across cancer types. High AGFG1 expression shows unfavorable associations in ACC, CESC, LIHC, UVM, BLCA and OV. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for AGFG1 RNA expression.
This table summarizes AGFG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for AGFG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGFG1 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, STAD and KIRP. The HNSC box plot shows higher AGFG1 RNA expression in tumor versus normal tissue (log2 FC = +0.791, t-test p < 0.001).
This table shows molecular features associated with AGFG1 in patient tissues and cancer cell lines. In patient samples, AGFG1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, AGFG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
